Brokers Issue Forecasts for Marinus Pharmaceuticals, Inc.’s Q1 2024 Earnings (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Equities researchers at Leerink Partnrs increased their Q1 2024 EPS estimates for Marinus Pharmaceuticals in a research report issued on Monday, April 15th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will earn ($0.61) per share for the quarter, up from their previous forecast of ($0.64). The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($2.29) per share. Leerink Partnrs also issued estimates for Marinus Pharmaceuticals’ Q2 2024 earnings at ($0.48) EPS, Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.70) EPS, FY2025 earnings at ($0.75) EPS, FY2026 earnings at ($0.05) EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.65 EPS.

Several other equities research analysts also recently commented on the stock. StockNews.com downgraded shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Robert W. Baird restated a “neutral” rating on shares of Marinus Pharmaceuticals in a research report on Tuesday. Truist Financial reduced their price target on shares of Marinus Pharmaceuticals from $25.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday. HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of Marinus Pharmaceuticals in a research report on Tuesday. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a research report on Monday, April 15th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $16.07.

Marinus Pharmaceuticals Stock Down 2.1 %

MRNS stock opened at $1.38 on Thursday. Marinus Pharmaceuticals has a 12 month low of $1.11 and a 12 month high of $11.26. The firm has a market cap of $75.80 million, a PE ratio of -0.52 and a beta of 0.91. The firm has a 50 day simple moving average of $8.37 and a 200 day simple moving average of $8.36. The company has a debt-to-equity ratio of 5.68, a current ratio of 4.07 and a quick ratio of 4.01.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. The business had revenue of $7.19 million for the quarter, compared to analyst estimates of $7.78 million. During the same period in the prior year, the company earned ($0.76) earnings per share.

Institutional Investors Weigh In On Marinus Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRNS. Point72 Asset Management L.P. purchased a new stake in Marinus Pharmaceuticals in the 4th quarter worth approximately $13,990,000. BlackRock Inc. lifted its position in Marinus Pharmaceuticals by 245.4% in the 2nd quarter. BlackRock Inc. now owns 3,897,770 shares of the biopharmaceutical company’s stock worth $42,330,000 after buying an additional 2,769,357 shares in the last quarter. Eventide Asset Management LLC increased its stake in shares of Marinus Pharmaceuticals by 42.8% during the 3rd quarter. Eventide Asset Management LLC now owns 4,529,997 shares of the biopharmaceutical company’s stock worth $36,466,000 after purchasing an additional 1,356,800 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Marinus Pharmaceuticals by 58.4% during the 3rd quarter. Jennison Associates LLC now owns 2,955,343 shares of the biopharmaceutical company’s stock worth $23,791,000 after purchasing an additional 1,089,913 shares during the last quarter. Finally, Millennium Management LLC increased its stake in shares of Marinus Pharmaceuticals by 415.7% during the 4th quarter. Millennium Management LLC now owns 1,082,759 shares of the biopharmaceutical company’s stock worth $4,309,000 after purchasing an additional 872,782 shares during the last quarter. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.